| Gene symbol | CLU | Synonyms | AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p21.1 | dbXrefs | |
| Description | clusterin | ||||
| GTO ID | GTC1199 |
| Trial ID | NCT00054106 |
| Disease | Prostate Cancer |
| Altered gene | CLU |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-011|custirsen sodium|TV-1011 |
| Co-treatment | buserelin|flutamide|conventional surgery|neoadjuvant therapy |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer |
| Year | 2003 |
| Country | Canada |
| Company sponsor | NCIC Clinical Trials Group |
| Other ID(s) | I153|CAN-NCIC-IND153|ONCOGENEX-OGX-01-01|CDR0000269888 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||